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Summary
 
Progressive infection with 
 
Leishmania major
 
 in susceptible BALB/c mice is mediated by interleu-
kin (IL)-4–producing T helper cell type 2 (Th2) CD4
 
1
 
 T cells that, once established, become
resistant to Th1-deviating therapies with recombinant (r)IL-12 and/or neutralizing anti–IL-4
antibodies. We sought to restore protective immunity in advanced leishmaniasis by depletion
of Th2-biased CD4
 
1
 
 populations and by cytokine-directed reconstitution of Th1 cellular re-
sponses during lymphocyte recovery. Treatment with cytolytic GK1.5 anti-CD4 mAb alone
did not reverse disease in 3 wk–infected BALB/c mice, but GK1.5 combined with anti–IL-4
antibody and intralesional rIL-12 cured cutaneous lesions in 80% of mice and established a
Th1-polarized cytokine response to 
 
L
 
.
 
 major
 
 antigen protective against reinfection. The cura-
tive effects of GK1.5 were not replaced by cytotoxic anti-CD8 monoclonal antibody 2.43 or
nondepleting anti-CD4 mAb YTS177, confirming that depletion of CD4
 
1
 
 cells was specific
and essential for therapeutic effect. Finally, combined CD4
 
1
 
 depletion and IL-4 neutralization
were curative, indicating that neither increased parasite burden nor altered accessory cell func-
tion independently biased towards Th2 reconstitution in advanced leishmaniasis. Advanced
leishmaniasis can be cured by T cell depletion and cytokine-directed recovery of Th1 cellular
responses, suggesting novel interventions for other immune-mediated diseases and identifying
distinct roles for CD4
 
1
 
 T cell and non-T cell in the maintenance of Th2 and Th1 phenotypes.
Key words: T helper cells type 2/immunology • interferon type II • interleukin 12 • T helper 
cells type 1/immunology • immunity/cellular
 
A
 
fter repeated stimulation, CD4
 
1
 
 T cells differentiate
into functionally distinct subsets defined by the pat-
terns of cytokine they produce (1). Although this provides
an efficient mechanism for tailoring specific host responses
to distinct infectious threats, inappropriate T cell functional
responses may cause pathology. For instance, Th1-type T
cells that produce proinflammatory cytokines normally in-
volved in antimicrobial defense, such as IFN-
 
g
 
 and TNF-
 
a
 
,
also mediate autoimmune disease when they acquire self-
reactivity (2). Th2-type T cells that produce variable com-
binations of IL-4, IL-5, and IL-13 and are important for re-
sistance against intestinal helminths (3) will mediate allergic
diseases when sensitized against common environmental
antigens (4, 5). Some immune-mediated pathologies can be
prevented experimentally if the opposite cytokine polarity
is preselected by treatment with differentiation-biasing cy-
tokines or anticytokine antibodies. For instance, immune
deviation towards Th2 responses prevents the expression of
autoimmune encephalomyelitis (6, 7), whereas deviation
towards Th1-biased antigen-specific responses blocks the
expression of allergic disorders (8). Once established, pro-
gressive forms of Th1 or Th2 immunopathology become
increasingly resistant to immunologic redirection by in vivo
cytokine therapy. An alternative approach to the therapy of
immune-mediated diseases is the depletion of immuno-
pathogenic CD4
 
1
 
 T cell populations by treatment with cyto-
toxic anti-CD4 antibody, an intervention already under
study in humans with severe rheumatoid arthritis (9). How-
ever, T cell depletion only transiently suppresses autoimmu-
nity in mice and humans, and disease typically relapses with
the recovery of Th1 CD4
 
1
 
 T cells (10, 11, 12). These find-
ings suggest that CD4
 
1
 
 depletion alone has limited efficacy
if it does not alter the intrinsic immune biases originally re-
sponsible for disease onset. In these studies, we address the
possibility that the recovery of CD4
 
1
 
 T cells after transient
depletion restores susceptibility to phenotype-biasing cy-
tokine therapy, and thereby permits the stable reversal of an
immunopathogenic T cell response.
We tested this hypothesis using a mouse model of pro-
gressive cutaneous leishmaniasis that is mediated by CD4
 
1
 
Th2 responses that become solidly resistant to anti-CD4
mAb or cytokine therapies once disease is established for 
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.
 
2 wk. Cutaneous infection of different inbred strains of
mice with 
 
Leishmania major
 
 provides a well-characterized sys-
tem suitable for the study of polarized cytokine responses
that mediate widely divergent disease outcomes (13). Disease-
resistant strains of mice cure subcutaneous infection with
 
L. major
 
 due to the IL-12–dependent expansion of Th1 type
CD4
 
1
 
 T cell responses that produce IFN-
 
g
 
, a proinflamma-
tory cytokine essential for nitric oxide–dependent killing of
the intracellular amastigote forms of 
 
Leishmania
 
. In contrast,
disease-susceptible BALB/c rapidly expand CD4
 
1
 
 T cells
populations committed towards production of the Th2 cy-
tokine IL-4 (14). IL-4 critically disrupts IFN-
 
g
 
–dependent
activation of tissue macrophages that are the obligate cellu-
lar target for this parasite (15). Survival of the pathogen
leads to progression of cutaneous lesions and permits even-
tual visceral dissemination.
Although the development of Th2 responses and pro-
gressive disease in 
 
L
 
.
 
 major
 
–infected BALB/c mice is pre-
vented by early treatment with anti–IL-4 antibody or rIL-12,
these interventions do not reverse T cell polarity or the dis-
ease outcome once infection is established for 
 
.
 
2 wk (16,
17). The resistance of Th2 cells to immune deviation may
reflect downregulation of IL-12 receptor function and con-
tinual self-renewal due to the biasing effects of IL-4 on the
expansion of precursor CD4
 
1
 
 T cells committed towards
Th2 development (18). Whether factors extrinsic to CD4
 
1
 
T cell function independently contribute to the phenotypic
stability of Th2 responses in established progressive leish-
maniasis is unresolved. Increased parasitic burdens poten-
tially affect T cell differentiation by altering the costimula-
tory competence of heavily parasitized accessory cells (19)
or by qualitatively perturbing T cell activation due to anti-
gen excess (20). Consistent with this, the Th2 response of
progressively infected BALB/c mice can be reversed by
IL-12 or anti–IL-4 mAb immunotherapy if the infectious
burden is first reduced by treatment with the leishmanicidal
antibiotic, sodium stibogluconate (21). Spontaneous or anti-
biotic-induced cure of visceral leishmaniasis in humans also
results in deviation towards Th1 immune responses (13). The
successful treatment of progressive leishmaniasis with CpG-
enriched oligonucleotides (22), which act directly on ac-
cessory cell populations (23), further supports a critical role
for T cell extrinsic factors in the experimental reversal of
established Th2 cytokine phenotypes.
In the study presented here, we examined whether anti-
body-mediated removal of dysfunctional Th2 CD4
 
1
 
 T cell
populations and their cytokine products is sufficient to
restore Th1 differentiating capacity in advanced murine
leishmaniasis in the absence of antibiotic therapy. We hy-
pothesized that transient depletion of CD4
 
1
 
 T cells not
only removes established Th2 cell populations responsible
for disease progression, but also results in the subsequent
outgrowth of CD4
 
1
 
 T cells that are susceptible to the dif-
ferentiating effects of Th1-selective rIL-12 or anti–IL-4
mAb therapies. Our findings demonstrate that CD4
 
1
 
 deple-
tion combined with IL-4 neutralization is sufficient to pro-
mote stable deviation towards a Th1 phenotype, with sub-
sequent decreases in parasite load and curing of cutaneous
 
lesions. This suggests a novel approach to the immunother-
apy of Th2-dependent diseases, and also demonstrates that
the immune environment of progressively infected BALB/c
mice is preferentially supportive of de novo Th1 responses
after the removal of Th2 CD4
 
1
 
 T cell activities that are in-
trinsically resistant to phenotypic reversal.
 
Materials and Methods
 
Mice.
 
4–6-wk-old female C57BL/6 and BALB/c mice were
purchased from The Jackson Laboratory and housed in the Case
Western University animal facility under specific pathogen-free
conditions.
 
Parasite Cultivation and Mouse Infection. L. major
 
 (WHO strain
WHOM/IR/
 
2
 
/173) were grown in M199 medium (GIBCO
BRL) containing antibiotics, supplemental glutamine, and 30% FCS
(HyClone Labs.), as previously described (24). Stationary phase
promastigotes were injected into the hind feet of recipient mice
at a dose of 2 
 
3
 
 10
 
6
 
 organisms per footpad to initiate infection.
The course of infection was monitored by measuring the thick-
ness of footpad swelling weekly using a dial gauge caliper. Soluble
 
L. major
 
 antigen was made as previously described (24).
 
Reagents.
 
Hybridomas producing cytotoxic anti-CD4 mAb
GK1.5 (rat IgG2b), anti-CD8 mAb 2.43 (rat IgG2b), neutralizing
anti–I-A
 
d
 
/I-E
 
d
 
 M5/114 (rat IgG2b), and neutralizing anti–IL-4
mAb 11B11 (rat IgG1) were obtained from the American Type
Culture Collection. Noncytotoxic anti-CD4 mAb YTS 177.9
(rat IgG2a) was obtained from Dr. Shixin Qin (Leukosite Inc.,
Boston, MA). Antibodies were generated using serum-free media
supplemented with 1% Nutridoma-NS (Boehringer Mannheim)
or by induction of nude mouse ascites, and were purified using
HiTrap Protein G columns (Pharmacia). Recombinant IL-12 was
generated in dihydrofolate reductase–deficient CHO-DUXB11
cells transfected with mouse p35 and p40 IL-12 cDNA coex-
pressing dihydrofolate reductase (Genetics Institute), and subse-
quently was incubated in increasing concentrations of methotrex-
ate to amplify transgene expression, as previously described (25).
IL-12 was purified from serum-free culture supernatant by se-
quential Mono Q and heparin-Sepharose (Pharmacia) affinity chro-
matography, and the specific IFN-
 
g
 
–inducing activity (1.1 
 
3
 
 10
 
6
 
U/mg) was determined in cultures of normal splenocytes, as pre-
viously described (26). As indicated in the figure legends, we used
rIL-12 (sp. act. 2.1 
 
3
 
 10
 
6
 
 IFN-
 
g
 
–inducing U/mg) provided by
Dr. M. Gately (Hoffmann-LaRoche, Nutley, NJ) as an alternative.
 
Culture of Lymph Node Cells.
 
Lymph node cells were washed
three times in HBSS, counted, and suspended in DMEM/10%
fetal bovine serum (FBS)
 
1
 
 (DMEM supplemented with 100 
 
m
 
g/ml
of penicillin and streptomycin, 2 mM glutamine, 0.1 mM nones-
sential amino acids, and 10% FBS, buffered at pH 7.4 with 10 mM
Hepes). Cells were aliquoted into flat-bottomed 96-well culture
plates at 10
 
6
 
 cells per well and cultured for 48 h in DMEM/10%
FBS. Stimuli included media alone or media containing soluble
leishmania antigen at 10–20 
 
m
 
g/ml. Where indicated, 10 
 
m
 
g/ml
of M-1 anti–IL-4 receptor mAb (Genzyme) was added to culture
to prevent IL-4 sequestration by soluble or cell-associated IL-4
receptor (27). Anti-MHC II mAb was added at 10 
 
m
 
g/ml to de-
termine the MHC II dependence of antigen-inducible cytokine
responses (28).
 
1
 
Abbreviations used in this paper:
 
 FBS, fetal bovine serum; iNOS, inducible
nitric oxide synthase. 
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Figure 1. Treatment with Th1-
deviating rIL-12 and anti–IL-4
antibodies or transient depletion
of CD41 T cells fails to cure es-
tablished murine leishmaniasis in
susceptible BALB/c mice. (A)
Combined treatment with neu-
tralizing anti–IL-4 mAb (11B11)
and rIL-12 does not reverse
established infection. BALB/c
mice (n 5 6 per group) were
infected with L. major and treated
with (Control) 0.5 mg of rat IgG
administered on days 7, 14, and
21 of infection (control) or 1.0 mm
of rIL-12 (Hoffmann-LaRoche;
2.1  3 103 U/dose) injected
intraperitoneally daily for 14 d
starting on day 7 of infection. A separate group of mice (11B11/rIL-12) were injected intraperitoneally on days 7, 14, and 21 with 1.0 mg of neutralizing
anti–IL-4 mAb 11B11 in combination with rIL-12 for 14 d. Shown are mean footpad thicknesses 6 SEM. Although footpad swelling was significantly
suppressed, all mice eventually progressed to develop ulceration and deep tissue necrosis. (B) Separate groups of BALB/c mice (n 5 5 each) were infected
with L. major for 3 wk and treated on days 21 and 22 with rat IgG (control) or with 0.33 mg of anti-CD4 mAb GK1.5 by intraperitoneal injection. An-
other group (11B11/rIL-12) was treated on day 21 with 1.0 mg of anti–IL-4 mAb 11B11 and then with 0.5 mg of rIL-12 given by intralesional injection
into each footpad (Hoffmann-LaRoche; 1.1 3 103 U/dose) for 8 consecutive days. All mice progressed to develop ulceration and necrosis.
 
Cytokine ELISA Assays.
 
Culture supernatants were assayed
for murine cytokines using double sandwich mAb ELISA tech-
niques as previously described (27). Antibodies used for capture
of IL-4, IFN-
 
g
 
, and IL-12 p40 were BVD-6, R46A2, and 15.6,
whereas captured cytokine was detected using biotinylated anti-
bodies BVD-4, XMG1.2, and 17.8, respectively (PharMingen).
Recombinant mouse IFN-
 
g
 
, IL-4, and IL-12 used as standards in
ELISA were purchased from PharMingen or Genzyme.
 
Reverse Transcriptase PCR Analysis of Cytokine mRNA.
 
Lymph
node mRNA was isolated using STAT-60 (TelTest) and analyzed
by oligo-dT primed reverse transcription and subsequent PCR. The
techniques and primers used have been published previously (29).
 
Quantitative Parasite Cultures.
 
Approximately 0.2–0.3 gram of
footpad tissue was minced in 2 ml of M199/30 FCS medium,
crushed through a No. 200 stainless steel screen (Small Parts, Inc.),
and disrupted using a Ten-Broeck homogenizer. 50-
 
m
 
l aliquots
of footpad or lymph node suspension were serially diluted five-
fold in promastigote growth medium and incubated in flat-bot-
tomed 96-well plates at 26
 
8
 
C in humidified room air. Individual
wells were examined using an inverted microscope at 200
 
3
 
 at
2-d intervals for the presence of motile promastigotes. Data rep-
resent the geometric mean 
 
6
 
 SEM of the last positive reciprocal
dilution for each experimental group.
 
Statistics.
 
For comparisons of ELISA data, significance was as-
sessed using the nonparametric Mann-Whitney rank sum test.
Significant differences in disease outcome were determined by
contingency table analysis (Fisher exact test).
 
Results
 
Cytokine-based Therapy with rIL-12 and Neutralizing Anti–
IL-4 mAb in Combination Fails to Reverse Established Leishma-
niasis.
 
Since IL-4 antagonizes the immunoregulatory ef-
fects of IL-12 (30, 31), we tested whether neutralization of
IL-4 by anti–IL-4 mAb 11B11 would restore the therapeu-
tic benefit provided of rIL-12 in BALB/c mice infected
with 
 
L
 
.
 
 major
 
 for 2 wk, a time at which these agents are in-
dividually ineffective (16, 17, 32). Mice treated daily with
1 
 
m
 
g of intraperitoneal rIL-12 on days 7–21 only demon-
 
strated nonsignificant decreases in footpad swelling (Fig. 1
A). In contrast, lesional development was significantly de-
layed in mice injected intraperitoneally with 1 mg of anti–
IL-4 mAb 11B11 in combination with intraperitoneal rIL-
12 treatments on days 7, 14, and 21 of infection. However,
all mice treated with this combination still displayed pro-
gressive footpad swelling leading to ulceration and limb ne-
crosis. Similar results were obtained in a second experiment
where 1 mg of anti–IL-4 mAb was administered intraperi-
toneally starting at wk 3 of infection and in combination
with 10 d of intralesional rIL-12 injection (Fig. 1 B). As
previously reported (17), treatment at wk 3 with anti–IL-4
mAb alone only delayed disease progression without af-
fecting final outcomes (data not shown). Similarly, delayed
treatment of established leishmaniasis with anti–IL-2 mAb,
which is normally curative when started early in infection
(33), also failed to restore protective immunity when com-
bined with rIL-12 (data not shown). These studies indi-
cated that the neutralization of Th2-promoting cytokines
alone was insufficient to restore the therapeutic effects of
rIL-12 in 
 
L
 
.
 
 major
 
–susceptible mice with advanced disease.
Because established BALB/c Th2-biased T cell responses
proved highly resistant to cytokine-induced phenotypic re-
versal, we next tested whether transient CD4
 
1
 
 T cell deple-
tion might remove pathogenic immune responses, while
also providing a newly emergent population of T cells sus-
ceptible to cytokine-directed differentiation towards the
curative Th1 phenotype.
 
CD4
 
1
 
 T Cell Depletion Combined with rIL-12 and anti–IL-4
mAb Immunotherapy Cures Progressive Leishmaniasis.
 
Treat-
ment of BALB/c mice with the cytolytic antibody GK1.5
given in two doses of 0.5 mg each on days 21 and 22 of
 
L
 
.
 
 major
 
 infection resulted in CD4
 
1
 
 lymphopenia lasting
 
z
 
2–3 wk (Table I). Although this dose of antibody is cura-
tive when given during wk 1 of infection, we confirmed
that delayed therapy with CD4 cytolytic antibody GK1.5
alone had no effect on outcome (Fig. 1 B). Continued pro- 
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gression of disease was associated with the re-emergence of
lymph node CD4
 
1
 
 T cells and IL-4 production in response
to 
 
L
 
.
 
 major
 
 antigen (data not shown). This suggested that
the intrinsic bias of BALB/c mice towards Th2 develop-
ment in this disease was not disrupted by transient CD4
 
1
 
 T
cell depletion alone. Therefore, we examined the course of
cutaneous leishmaniasis in 3 wk–infected BALB/c mice
treated with GK1.5 in combination with anti–IL-4 11B11
mAb and intralesional rIL-12 administered during the 2-wk
period leading up to CD4
 
1
 
 T cell recovery. In control
BALB/c mice treated with nonspecific rat IgG, the cutane-
ous lesions progressed rapidly, as indicated by increasing
footpad thickness and the development of ulceration and
necrosis (Fig. 2). In contrast, mice treated with combined
GK1.5, rIL-12, and anti–IL-4 mAb were able to limit and
then reverse footpad swelling, with all five mice showing
complete resolution of disease (Fig. 2).
By wk 14 of infection, the hindlimb swelling of mice re-
ceiving GK1.5-based immunotherapy had diminished to an
average thickness compatible with that of age-matched
normal feet. To determine if successful immunotherapy
provided long-lasting immunity against reinfection with
 
L
 
.
 
 major
 
, these cured mice and a group of normal BALB/c
mice were infected with 2 
 
3
 
 10
 
6
 
 
 
L
 
.
 
 major
 
 promastigotes in
each hind foot. The immunotherapy-cured mice rapidly
contained reinfection by 4 wk, as indicated by the tran-
sience of footpad swelling, whereas control BALB/c mice
developed progressive footpad swelling characteristic of non-
healing leishmaniasis (Fig. 2).
The protective effects of GK1.5-based immunotherapy
were subsequently reproduced in four additional studies
where advanced cutaneous lesions were durably cured in
20 out of 25 BALB/c mice (80%). None of the 27 control
BALB/c mice recovered from infection (difference significant
at
 
 P 
 
, 
 
0.01, Fisher exact test). Decreased footpad swelling
 
was associated with reduced parasite load within the cutane-
ous lesions, with 42-fold decreases apparent at 3 wk after
treatment (10
 
9.59
 
 6 
 
0.41
 
 per gram of control tissue compared
with 10
 
7.96
 
 
 
6 0.24 for treated mice) and a further 10,000-fold
reduction evident at 7 wk after therapy (103.1 6 0.40 per gram).
BALB/c Mice Cured of L. major Infection by GK1.5-based
Immunotherapy Produce a Th1-polarized Cytokine Response.
The draining lymph node cells from five cured and rein-
fected mice were harvested, and their antigen-specific cy-
tokine responses were compared with infected, untreated
BALB/c mice (Table II). Although the amounts of IFN-g
stimulated by antigen were not significantly different be-
tween the two groups, immunotherapy-cured mice pro-
duced concentrations of IL-4 that were $20-fold reduced
relative to control BALB/c mice (P , 0.05). In a second
experiment in which two out of five treated mice failed to
heal, therapeutic success and failure correlated with the ab-
sence and presence of IL-4 production, respectively (Table
II). There was evidence that the restored CD41 T cell pop-
ulations contributed to IFN-g production, as synthesis of
this cytokine in treated and control mice was 46 and 60%
MHC II dependent, respectively. IL-4 production was re-
duced to undetectable levels in the presence of anti–MHC
II mAb. These findings indicated that the immunotherapy-
induced cure gave rise to antigen-specific CD41 T cell
populations producing IFN-g without IL-4, consistent
with protective immune deviation towards a unipolar Th1
phenotype.
CD41-specific Depletion Is Required for the rIL-12/Anti–IL-
4–mediated Cure of Established Murine Leishmaniasis. Although
Table I. Treatment with GK1.5 Anti-CD4 Antibody Transiently 
Depletes CD41 T Cells in BALB/c Mice Infected for 3 wk with
L. major
Days after GK1.5
Percentage of
CD4
Percentage of
CD8
0 30.3 6 1.9 12.6 6 0.9
3 5.4* (4.1) 27.4* (22.5)
7 5.9 6 1.9 21.2 6 0.7
21 14.6 6 1.1 20.4 6 1.2
63 18.6 21.4
Groups of five BALB/c mice were infected with L. major for 3 wk and
injected with 1.0 mg of GK1.5 mAb. Spleen cells were harvested at the
indicated number of days after injection with GK1.5 and the percent-
age of total cells expressing surface CD4 or CD8 was determined by
two-color FACS® analysis. Shown are mean percentage of cells positive
6 SEM (n 5 4).
*Cells were pooled in one group and the parentheses indicate the re-
sults from a separate experiment where data represent pooled lymph
node cells from four mice.
Figure 2. BALB/c mice infected for 3 wk with L. major can be cured
by CD41 depletion and Th1-deviating cytokine therapy. Groups of five
BALB/c mice were treated with (GK1.5/11B11/rIL-12) 0.5 mg of
GK1.5 mAb and 11B11 anti–IL-4 mAb given daily for 2 d, followed by a
total of 10 intralesional injections of 0.5 mg of rIL-12 (Hoffmann-
LaRoche; 1.1 3 103 U/dose) into each foot from days 21 through 32 or
0.5 mg of rat IgG and intralesional saline only (control). Data represent
mean footpad thickness 6 SEM measured weekly by micrometer. All
control mice were killed at 8 wk because of progressive cutaneous ulcer-
ation and necrosis; five out of five mice receiving GK1.5 immunotherapy
healed. At 14 wk of infection, the five BALB/c mice cured by immuno-
therapy and five normal BALB/c mice (reinfection control) were injected
with 2 3 106 L. major promastigotes per footpad and footpad thicknesses
recorded weekly.1899 Heinzel and Rerko
we hypothesized that the protective effects of GK1.5-based
immunotherapy were dependent on the removal of IL-
4–producing cells present in the CD41 T cell population,
noncytolytic effects of anti-CD4 antibody on the function
of MHC II–restricted T cells may have affected the out-
come separately. For instance, in vivo and in vitro Th2 de-
velopment requires that CD4 bind to MHC II during anti-
gen presentation, suggesting that neutralization of CD4
function alone might effectively substitute for cellular de-
pletion in the immunotherapy of established leishmaniasis
(34, 35). Another possibility requiring experimental exclu-
sion was that the process of in vivo cellular depletion, re-
gardless of the population targeted, was contributing di-
rectly or indirectly to cure of leishmaniasis and reversal of
Th2 dominance. To test these alternative hypotheses, sepa-
rate groups of BALB/c mice infected for 3 wk with L. major
were treated with anti–IL-4 antibody and intralesional
rIL-12 after receiving 0.5 mg of either depleting or nonde-
pleting anti-CD4 mAb (GK1.5 and YTS177, respectively)
or after being treated with depleting anti-CD8 mAb 2.43.
In pilot studies, YTS177 failed to reduce peripheral blood
CD41 counts by .15%, as previously described (36). Only
the immunotherapy regimen based on depleting GK1.5 an-
tibody was capable of healing the cutaneous lesions of pro-
gressive leishmaniasis (four out of six mice) (Fig. 3). These
experiments clearly indicated that specific depletion of
CD41 T cells was required to mediate the cure by com-
bined treatment with rIL-12 and anti–IL-4 and that deple-
tion of an alternative T cell subset did not invoke nonspe-
cific protective responses.
Effects of GK1.5-based Immunotherapy on IL-4 and IFN-g
Synthesis. We next determined how immunotherapy af-
fected the in vitro and in vivo cytokine responses of infected
mice at 7 and 21 d after treatment. The first time point cor-
responds to the inductive stage of immunotherapy, when
CD41 T cells were freshly depleted and the mice were re-
ceiving intralesional therapy with rIL-12. The second time
point corresponds to the subsequent repopulation of the
lymph node by CD41 cells. At 1 and 3 wk after the start of
immunotherapy, the popliteal lymph node cells of treated
mice produced approximately three- and sevenfold less
IL-4 in response to soluble leishmania antigen than did the
lymph node cells of control mice (Fig. 4). Consistent with
a predominantly CD41 T cell source for IL-4 in control
mice, IL-4 levels were reduced by z80% in the presence of
anti–MHC II antibodies capable of blocking both I-Ad and
I-Ed (data not shown). The small amounts of IL-4 produced
by CD41-depleted mice also remained MHC II depen-
dent, indicating that the residual IL-4 response was derived
from CD41 T cells that had escaped depletion.
The lymph node cells of treated mice produced twofold
more IFN-g than controls in the first week of therapy.
Some of this response may have been mediated by ongoing
rIL-12 therapy, as the majority of the IFN-g response was
spontaneous. By 3 wk after therapy, control and treated
mice produced similar amounts of IFN-g in response to
antigen. Although production of IFN-g in control lymph
Table II. Cure of Leishmaniasis after GK1.5-based 
Immunotherapy Is Associated with Unipolar Th1-type
Cytokine Responses
Group
Antigen-induced
cytokine levels
IFN-g IL-4*
ng/ml 6 SEM
Experiment 1
Control (n 5 5) 1.42 6 0.19 1.24 6 0.35
Immunotherapy (n 5 5) 0.88 6 0.39 0.06 6 0.02
Experiment 2
Uninfected 0.11 #0.05
Control (n 5 5) 1.36 6 0.07‡ 1.28 6 0.17
Immunotherapy (n 5 3) 1.01 6 0.12‡ 0.05
Nonhealing (n 5 2)§ 2.08 1.53
BALB/c mice were treated with GK1.5 and 11B11 mAb, followed by
intralesional rIL-12 as described in the text. Lymph node cells were
harvested after disease recovery at wk 4 of reinfection (Experiment 1)
or at wk 7 after immunotherapy (Experiment 2) and were cultured for
48 h in the presence of 10 mg/ml of soluble leishmania antigen. Cyto-
kine concentrations were measured by specific ELISA. Control lymph
node cells were from BALB/c mice infected for 4 wk with L. major.
*IL-4 was measured in antigen-stimulated cultures to which anti–IL-4
receptor mAb had been added (10 mg/ml). IL-4 levels in all cultures
were reduced by .96% in the presence of anti–MHC II mAb.
‡Antigen-stimulated IFN-g production was reduced 60.8 6 5.4% for
control mice and 46.3 6 7.5% for immunotherapy mice after neutral-
ization of MHC II by anti–I-Ed/I-Ad mAb added at 10 mg/ml to anti-
gen-stimulated cultures.
§Two mice failed therapy, as indicated by chronic footpad swelling and
cutaneous ulceration.
Figure 3. Specific depletion of CD41 T cells is required for cure of es-
tablished leishmaniasis in response to treatment with rIL-12 and anti–IL-4
mAb. Groups of five BALB/c mice were infected with L. major for 3 wk
and then injected on 2 consecutive d with 0.5 mg of rat IgG (control),
depleting anti-CD4 mAb GK1.5 (GK1.5), depleting anti-CD8 mAb
(Lyt2.2), or nondepleting anti-CD4 mAb YTS177.9 (YTS). All groups
except for controls were subsequently treated intraperitoneally with 1.0
mg of anti–IL-4 mAb 11B11 on day 21 and 1.0 mg of rIL-12 (1.1 3 103
U/dose) injected into each footpad daily for 8 d. Data represent footpad
thicknesses (in millimeters) measured weekly and displayed as mean 6
SEM. With the exception of GK1.5-treated mice, all groups developed
progressive ulceration and footpad necrosis.1900 Depletional Resetting of Cytokine Phenotypes in Murine Leishmaniasis
node cultures was reduced by 60% in the presence of anti–
MHC II antibodies (difference significant at P , 0.05),
IFN-g declined by only 18% (P . 0.10) when lymph node
cells from mice were cultured under the same conditions at
1 wk after treatment (data not shown). These findings indi-
cate that starting in the first week of immunotherapy
treated mice were markedly less able to produce MHC II–
dependent IL-4, but maintained antigen-specific IFN-g
synthesis by MHC II–unrestricted mechanisms before CD41
T cell recovery. In contrast, IFN-g responses were reduced
46.3 6 7.5% in the presence of anti–MHC II at 7–8 wk
after immunotherapy (Table II), indicating recovery of
CD41 T cell populations responsive to leishmania antigen
and biased towards the production of IFN-g without IL-4.
Immunotherapy Leads to Sustained Increases in the Expression
of mRNA Encoding Inducible Nitric Oxide Synthase, IL-12 p40,
and the IL-12 Receptor b2 Subunit. Compared with control
mice, expression of IFN-g mRNA increased twofold and
IL-4 mRNA expression decreased approximately threefold
in the lymph nodes of treated mice at 7 and 21 d after the
start of immunotherapy (Fig. 5). A separate group of 3 wk–
infected BALB/c mice treated with GK1.5 anti-CD4 alone
also demonstrated threefold decreases in IL-4 mRNA after
3 d (data not shown), consistent with reduced IL-4 produc-
tion as a result of CD41 depletion. Although the extent to
which IL-4 mRNA was decreased in vivo was less than
that measured for IL-4 protein in antigen-stimulated lymph
node cultures, treated mice also expressed ninefold more
inducible nitric oxide synthase (iNOS) mRNA relative to
control nodes. Because iNOS production is stimulated by
IFN-g, reciprocally inhibited by IL-4, and necessary for
curing of infection, increased iNOS mRNA expression in
treated mice confirms both the overall Th1 predominance
of the in vivo cytokine response and its significance with
regards to the development of leishmanicidal activity.
The induction and expansion of protective Th1 responses
in leishmaniasis is dependent on IL-12 synthesis by acces-
sory cells and functional IL-12 receptor expression by re-
sponder T cells. In this regard, the lymph nodes of treated
Figure 4. Early and delayed effects of GK1.5-based immunotherapy on
lymph node cytokine responses. Groups of six BALB/c mice each were
infected with L. major for 3 wk and treated with rat IgG alone (control) or
GK1.5 and anti–IL-4 mAbs combined with intralesional rIL-12 as described
in Fig. 2 (GK1.5/11B11/rIL-12). Lymph node cells were harvested at
7 and 21 d after the start of therapy and cultured in DMEM/10% FBS
alone or in the presence of 10 mg/ml of soluble leishmania antigen. Anti–
IL-4 receptor mAb (M-1) was added at 10 mg/ml in duplicate cultures to
measure total production of IL-4. After 48 h of culture, supernatants were
assayed by ELISA. Data represent mean cytokine concentrations (ng/ml)
6 SEM for IL-4 (top) and IFN-g (bottom). IL-4 production was de-
creased significantly (P , 0.05) for immunotherapy mice compared with
control mice for all times and conditions. IFN-g production increased
significantly (P , 0.05) for immunotherapy mice only during wk 1.
Figure 5. CD41 depletion and cytokine therapy restores Th1 type
mRNA responses in vivo while suppressing IL-4 mRNA expression.
RNA was harvested from lymph node tissues taken from control (C) and
GK1.5/11B11/rIL-12-treated (ITx) mice at 7 and 21 d after the start of
immunotherapy. Reverse transcriptase PCR was used to compare expres-
sion of selected immune response genes. Mice had been infected previ-
ously for 3 wk with L. major. Data represent the expression of the indi-
cated mRNA species as determined by densitometric analysis of gel
products obtained by semiquantitative reverse transcriptase PCR. Data
are normalized for expression of HPRT in the same sample. Expression of
IL-4, IFN-g, IL-12 receptor b2, and iNOS mRNA was not detectable in
naive lymph node tissue at the level of amplification used in these analy-
ses. Primers used for amplification of IL-12 receptor b2 cDNA were
(59 to 39): GCACAGACTGTTAGAGAATGC (sense) and CCTTCCTG-
GACACATGATATG (antisense). Primers for murine iNOS cDNA
amplification were: TCACGCTTGGGTCTTGTTCACT (sense) and
TTGTCTCTGGGTCCTCTGGTCA (antisense).1901 Heinzel and Rerko
mice expressed threefold more IL-12 p40 mRNA than did
those of control mice at 7 and 21 d after immunotherapy.
This correlated with increased spontaneous secretion of
IL-12 p40 protein in lymph node cultures at 21 d after im-
munotherapy (0.37 6 0.11 ng/ml for treated compared
with 0.19 6 0.01 ng/ml for control mice; P , 0.05). Fi-
nally, IL-12 receptor b2 subunit mRNA was increased
threefold in the lymph node tissue of treated compared
with control mice. The IL-12Rb2 subunit is required for
transduction of IL-12–dependent signals in CD41 T cells
and its rapid downregulation in BALB/c mice under neu-
tral conditions is thought to be essential to the preferential
development of Th2 cells when mice of this strain are in-
fected with L. major (18, 37). Therefore, these in vivo–
based findings confirm that the shift towards Th1-polarized
cytokine responses after GK1.5 based immunotherapy is
accompanied by enhanced IL-12 production and IL-12 re-
sponsiveness necessary for the induction and maintenance
of protective immunity.
CD41 T Cell Depletion and Anti–IL-4 mAb Constitute the
Minimum Effective Immunotherapy. Although these studies
were initially designed to reconstitute the therapeutic effect
of rIL-12 in the setting of progressive leishmaniasis, we also
addressed the possibility that CD41 depletion followed by
neutralization of IL-4 alone was sufficient to achieve a cure.
Groups of BALB/c mice infected for 3 wk with L. major
were treated with GK1.5 and 11B11 with or without a 10-d
course of intralesional injection with rIL-12 (Fig. 6). Sur-
prisingly, mice treated with GK1.5 and anti–IL-4 mAb
healed at the same rate regardless of the presence or absence
of intralesional rIL-12 in the immunotherapeutic protocol.
The only notable difference between the two groups was
the transient suppression of footpad swelling during the 2-wk
period in which mice were actively treated with rIL-12.
Furthermore, rIL-12 could not substitute for anti–IL-4 in
the restoration of curative immunity in GK1.5-treated
mice. In a separate experiment (data not shown), the com-
bination of GK1.5 and rIL-12 cured only one out of six
mice previously infected for 3 wk, whereas a combination
of GK1.5, anti–IL-4 11B11 mAb, and rIL-12 cured four
out of six mice. These data indicated that suppression of
IL-4 bioactivity alone was sufficient to permit the establish-
ment of unipolar Th1 cytokine responses after GK1.5
treatment of BALB/c mice with advanced infection with
L. major.
Discussion
In these studies, we demonstrate that transient depletion
of Th2-biased CD41 T cell responses in 3-wk L. major-
infected BALB/c mice restores the therapeutic Th1-differ-
entiating effects of anti–IL-4 mAb, with or without the
addition of rIL-12. The mechanisms mediating protection
included a requirement for specific depletion of CD41 T
cells, as merely blocking CD4 function with nondepleting
anti-CD4 antibody did not change the course of disease.
Similarly, selective depletion of CD8 cells also failed to
restore the cure in response to cytokine therapy and it is
unlikely that the process of cellular depletion itself non-
specifically contributed to parasite clearance. Therefore,
GK1.5-based immunotherapy appears to mediate protec-
tion by durably ablating Th2 CD41 T cells responsible for
the progression of leishmaniasis, while permitting the even-
tual recovery of curative, MHC II-dependent IFN-g re-
sponses—effectively “resetting” the CD41 T cell immune
phenotype at the populational level. The protective effects
of GK1.5-based immunotherapy were reproduced in five
groups of mice and resulted in the cure of advanced cuta-
neous lesions in 20 out of 25 animals (80%). Once cured,
these cutaneous lesions did not recur during a 14-wk pe-
riod of observation and mice that had recovered after im-
munotherapy were fully resistant to reinfection with a large
inoculum of L. major. These findings confirm the stable re-
versal of antigen-specific Th2 responses by a combination
of CD41 elimination and therapy-directed Th1 expansion.
Surprisingly, BALB/c mice with advanced infection and
genetic predispositions towards Th2 development were fully
capable of supporting unipolar Th1 responses provided only
that IL-4 activity was neutralized at the time of CD41 T
cell recovery.
Recovery of leishmanial skin lesions was notably delayed
and coincided with the onset of lymphoid tissue repopula-
tion by CD41 T cells expressing a Th1 cytokine phenotype.
Footpad thickening initially continued for up to 4 wk after
treatment with GK1.5, anti–IL-4 mAb, and rIL-12, with
z25% of the cutaneous lesions progressing to shallow ulcer-
ation before healing began. The parasite load within the cu-
taneous lesions also declined after a significant delay, with
relatively minor 42-fold decreases apparent at 3 wk after
treatment and a more substantial 10,000-fold reduction ap-
parent at 7 wk after therapy. Although T cell populations
of untreated animals produced both IL-4 and IFN-g in re-
Figure 6. The combination of transient CD41 T cell depletion and
anti–IL-4 mAb therapy alone is sufficient to cure L. major–infected
BALB/c mice. Groups of five BALB/c mice each were infected with L.
major for 3 wk and treated with saline alone (control) or with 0.5 mg of
anti-CD4 mAb GK1.5 on days 21 and 22 of infection and 1.0 mg of anti–
IL-4 mAb 11B11 on day 22 combined with 10 d of intralesional rIL-12
administered at 1.0 mg per footpad (1.1 3 103 U/dose) (GK1.5/11B11/
rIL-12) or GK1.5 and 11B11 given without rIL-12 (GK1.5/11B11). Data
represent mean footpad thicknesses (mm) 6 SEM at weekly intervals.1902 Depletional Resetting of Cytokine Phenotypes in Murine Leishmaniasis
sponse to L. major antigen, lymph node cells from BALB/c
mice treated 3 wk previously with GK1.5, 11B11, and rIL-12
produced IFN-g in similar quantities, but with sevenfold
reduced synthesis of IL-4. IL-4 production was undetect-
able in BALB/c mice that had been cured for 19 wk and
that demonstrated resistance to infection. This was ob-
served not only in comparison to control BALB/c mice in-
fected with L. major, but also in comparison to the few
mice that failed to heal after immunotherapy and that pro-
duced amounts of IL-4 no different than untreated con-
trols. IL-4 productive capacity was similarly unchanged af-
ter ineffective treatment with anti–IL-4 and rIL-12 alone
or with GK1.5 alone (data not shown). Treatment also in-
creased expression of IL-12 p40, IL-12 receptor, and iNOS
mRNA in the draining lymph nodes, indicating the bio-
logically significant restoration of IL-12–dependent cyto-
kine cascades and Th1-dependent leishmanicidal defenses.
Because IFN-g synthesis was greater than 50% MHC II-
dependent in healing mice, these findings are most consis-
tent with the delayed recovery of advanced lesions in re-
sponse to repletion of a CD41 T cell population expressing a
unipolar Th1 phenotype capable of activating nitric oxide–
dependent parasite killing.
We first confirmed that monotherapy with rIL-12, anti–
IL-4 mAb, or GK1.5 at wk 2–3 of infection had no lasting
effect on the progression of disease, although they are cura-
tive when given in wk 1 of infection. Because rIL-12,
GK1.5, and anti–IL-4 have been reported to alter the course
of leishmaniasis when given as late as 14 d after infection in
other studies (16, 17, 38), we studied the effects of immu-
notherapy at wk 3 to further ensure that monotherapy would
be ineffective. Under these stringent conditions, none out
of 18 mice treated with rIL-12, anti–IL-4 mAb, or GK1.5
alone were able to cure disease. Combinations of anti–IL-4
and rIL-12 therapies were also ineffective when started as
early as day 7 of infection. Although IL-4 is necessary for
Th2 development in L. major–infected BALB/c mice, the
well-characterized inhibitory effects of this cytokine on
IL-12 receptor expression and rIL-12–directed Th1 cell
differentiation (18, 30, 31) do not appear to be necessary
for maintaining the in vivo resistance of established Th2
CD41 T cells to rIL-12 therapy. Once developed, the Th2
CD41 T cells of BALB/c mice either do not require IL-4
to maintain numbers and function, or else impractically large
doses of anti–IL-4 antibody are necessary to adequately neu-
tralize IL-4 bioactivity in vivo.
However, relatively low doses of anti–IL-4 mAb were
both sufficient and essential for establishing curative immu-
nity after GK1.5 treatment of L. major–infected BALB/c
mice. In this regard, the recovering CD41 T cells of GK1.5-
treated mice appear to be functionally similar to those
present in wk 1 of infection, when anti–IL-4 mAb prevents
the expansion of Th2 cells by preserving IL-12 responsive-
ness (30). We observed residual IL-4 in GK1.5-treated ani-
mals. This probably derived from cytolysis-resistant CD41 T
cells, as antigen-induced IL-4 production remained MHC II
dependent in these mice. The failure to eradicate .85% of
CD41 T cells in infected mice, compared with .95% in un-
infected mice (data not shown), is compatible with previous
demonstrations of the relative resistance to GK1.5-mediated
depletion of T cells with a memory/effector phenotype (39).
The residual IL-4 production by CD41 T cell–depleted
mice was not immediately affected by additional treatments
with rIL-12 and anti–IL-4 mAb (data not shown), but de-
clined gradually over a 3-wk period. This suggests that
anti–IL-4 mAb limited re-expansion of Th2-committed T
cells in infected mice without directly inhibiting residual
IL-4 synthesis, consistent with recent demonstrations of cyto-
kine-autonomous production of IL-4 in differentiated Th2
cells (40, 41). These data otherwise do not determine
whether the GK1.5-resistant cellular sources of IL-4 even-
tually disappear due to attrition, suppression, or phenotypic
reversal at the cellular level. Instead, the recovering CD41
T cell population was biased towards production of IFN-g.
Although Th1-biasing cytokine therapy may have prefer-
entially affected undifferentiated precursor CD41 T cells
that were recent thymic emigrants (42), a subset of periph-
eral memory/effector cells susceptible to differentiating cy-
tokines may have provided an alternative source for the re-
constituted Th1 response (43). Further investigations are
needed to distinguish between these mechanisms.
Other mechanisms may have contributed to the GK1.5-
induced cure of BALB/c leishmaniasis. Our studies suggest
that CD81 T cells and/or NK cells were interim sources of
IFN-g in the first week after CD41 depletion and cytokine
therapy, when IFN-g synthesis was maintained and was
transiently MHC II independent. Although resistant strains
of mice deficient in either b2-microglobulin or CD81 T
cells remain capable of curing primary infection with L. major
(44, 45), MHC I–restricted responses have been implicated
in the late recovery and subsequent resistance to reinfection
(38). Detailed studies beyond the scope of the current re-
port will be required to determine if the CD81 T cells of
disease-susceptible BALB/c mice mediate beneficial func-
tions that are otherwise silenced in the face of functionally
dominant Th2-type CD41 T cell responses. These studies
also do not exclude selective tolerization of parasite-specific
Th2 cells as an alternative curative mechanism for GK1.5-
based immunotherapy. Treatment with cytolytic anti-CD4
mAb establishes antigen-specific immunologic tolerance and
protects against Th1-mediated autoimmune pathologies in
mice (46). The preservation of MHC II–dependent, L. major–
specific IFN-g production in GK1.5/11B11/rIL-12–treated
BALB/c mice indicates that any tolerizing effects were lim-
ited to Th2-inducing antigens, which are known to protect
against disease when induced by other methods (47). How-
ever, noncytolytic anti-CD4 mAb YTS177 that tolerizes
developing immune responses in other disease models (36)
failed to cure leishmaniasis in combination with anti–IL-4
mAb and rIL-12. These findings therefore favor depletion
as the relevant protective mechanism.
The cure of established murine leishmaniasis by deple-
tion-induced phenotypic “resetting” of the CD41 T cell
population is not the first form of successful immunother-
apy in this model of T cell–dependent pathology, but the
mechanisms involved appear to be distinct. For instance,1903 Heinzel and Rerko
cure by combined treatment with rIL-12 and sodium stibo-
gluconate was associated with a Th2 to Th1 shift only after
parasite burden was reduced (21). Although the central role
of Th2 cytokines in the initiation of progressive leishma-
niasis is well characterized, increased parasite burdens may
subsequently contribute to sustaining the susceptible state
by independently biasing towards Th2 differentiation and
function. For instance, leishmania-infected accessory cells
are less able to produce IL-12 and to respond to IFN-g (19,
48). Increased antigenic stimulation of BALB/c T cell re-
ceptors also independently favors the differentiation of T
cells with Th2 phenotypes (20). Finally, CD28-directed
costimulatory signals are necessary for Th2, but not Th1
immune responses in murine leishmaniasis and further im-
plicate accessory cell function in regulating CD41 cytokine
polarity (49, 50). However, mice cured by “CD4 reset”
showed their greatest declines in parasite burden after the
recovery of Th1 CD41 T cell responses at wk 3 of therapy.
This is most consistent with parasite killing as a result of
Th1 immune deviation within the CD41 T cell population,
rather than immune deviation in response to reduced infec-
tious burden. Therefore, these findings suggest that increased
parasite load, increased antigen presentation, or altered
accessory cell costimulatory function are not sufficient by
themselves to reconstitute a Th2-biased response after CD41
T cell depletion. We conclude that the perpetuation of cyto-
kine-resistant Th2 T cell responses in progressive leishma-
niasis is dependent on properties of the CD41 T cell and is
not independently determined by infection-induced changes
in the non-CD41 T cell immune environment.
These studies are significant more generally in that they
demonstrate the potential to reverse established, pathologic
CD41 T cell responses by combined antibody-directed cy-
tolysis and subsequent treatment with differentiating cyto-
kines or anticytokine antibodies. Our ability to modulate
Th2 responses is especially remarkable because of the well-
recognized stability of this phenotype to immunotherapeu-
tic reversal (16, 32, 51, 52) and indicates the potential for
use as immune-deviating therapy in other Th2-dependent
experimental and clinical diseases. A similar approach to the
reversal of severe allergic disorders is technically feasible, as
cytolytic anti–human CD4 antibodies are already in experi-
mental use for autoimmunity, and Th1-deviating agents,
such as soluble IL-4 receptor and rIL-12, are in various
stages of clinical investigation. By analogy, Th1-dependent
autoimmune diseases might also be reversible if stable devi-
ation towards a Th2 phenotype results in disease suppres-
sion (53, 54). The pathogenic Th1 responses of murine
autoimmune encephalomyelitis, lupus nephritis, and col-
lagen-induced arthritis can be prevented by pretreatment
with anti-CD4 antibodies that tolerize against the inducing
antigen. However, as in leishmaniasis, established and pro-
gressive forms of disease only briefly remit after short-term
treatment with anti-CD4 mAb (10, 36). We speculate that
GK1.5 treatment of advanced autoimmunity might restore
CD41 T cell populations with naive-like susceptibility to
the Th2-deviating effects of anti–IL-12 antibodies or rIL-4
that otherwise only prevent disease expression when given
at the time of sensitization to self-antigen (55, 56). In
conclusion, these studies show that curative and unipolar
Th1 cellular responses are recovered in heavily parasitized,
disease-susceptible mice merely by transient depletion of
CD41 T cells and neutralization of residual IL-4 bioactiv-
ity. Because CD41 T cell depletion provides a unique win-
dow of opportunity to durably reprogram the cytokine
polarity of an established and pathogenic T cell response,
these findings suggest a novel immunotherapeutic strategy
potentially applicable to the clinical amelioration of pro-
gressive allergic and autoimmune disorders.
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